Taisho Pharmaceutical Co. Ltd. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

April 2024 | 50 pages | ID: T0F524DB361BEN
BAC Reports

Abstracts

Taisho Pharmaceutical Co. Ltd. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Taisho Pharmaceutical Co. Ltd. and its competitors. This provides our Clients with a clear understanding of Taisho Pharmaceutical Co. Ltd. position in the Pharmaceuticals and Biotechnology Industry.

• The report contains detailed information about Taisho Pharmaceutical Co. Ltd. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
• Another part of the report is a SWOT-analysis carried out for Taisho Pharmaceutical Co. Ltd.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
• The Taisho Pharmaceutical Co. Ltd. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
• In the part that describes Taisho Pharmaceutical Co. Ltd. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
• Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Taisho Pharmaceutical Co. Ltd. business.

About Taisho Pharmaceutical Co. Ltd.

Taisho Pharmaceutical Company, Ltd. offers pharmaceuticals and health-related products, as well as health-related information and services.

SEGMENTS

The company operates its business in two segments: Self-medication, such as OTC products, customer goods for household and general use, and other products; Pharmaceuticals, such as Ethical drugs.

Self-Medication Segment

The self-medication business is one of Taisho Pharmaceutical's mainstay operations. It promotes ‘switch Rx-to-OTC’ products, incorporating active ingredients in prescription drugs into over-the-counter medicines, and opening up new fields with the creation of the Livita (derived from Life Vitality Support) brand of foods scientifically proven to be safe and useful for promoting health.

Products: The company offers Self-Medication products such as the cold remedy Pabron, the gastrointestinal treatmentsTaisho Kanpo Ichoyaku, Avalon and Balancer Ichoyaku and the laxative Colac; and quality-of-life improvement products, such as the nutrient drink Lipovitan D, the hair-growth treatment RiUP, and the Livita series of ‘foods for specified health use’.

Marketing: The company offers its self-medication main product line Lipovitan in approximately 19 countries, principally in Hong Kong, Taiwan, Malaysia, the Philippines, Indonesia, Thailand, Vietnam, China, Australia, the United States, and the United Kingdom.

Pharmaceuticals Segment

In prescription pharmaceuticals, Taisho is implementing a structure to continuously create new drugs for domestic and overseas use. In research and development, Taisho conducts in-house programs and develops tie-ups with corporations and research facilities in Japan and overseas. The company reinforced its network for gathering information from research centers in Japan, the United States and Europe to stay abreast of the latest information in pharmaceutical research. New computer-based technologies, such as genome analysis and sequence determination, screening and combinatorial chemistry, have significantly improved the quality and speed of new drug development. Taisho Toyama Pharmaceutical Co., Ltd., a sales subsidiary jointly established with Toyama Chemical Co., Ltd., is helping to expand sales channels as the company build on its efficiency in the infectious disease and anti-inflammatory fields.

Products: Taisho markets approximately 20 products in Japan and approximately 90 countries worldwide, including Clarith, a macrolide antibiotic; Palux injection, a peripheral vasodilator; a nonsteroidal anti-inflammatory drug Lorcam tablets; Ancaron tablets for the treatment of cardiac arrhythmia; and an anti-ulcer agent Solon. In partnership with the medical community, Taisho works to develop market-oriented products, and through its capital and administrative tie-up with Toyama Chemical Co., Ltd., the company is striving to deliver a lineup of medications and treatments to help people in Japan and around the world richer lives by improving their health.

Alliance: The company has a business alliance with Toyama Chemical Co., Ltd., Taisho established a new joint venture Taisho Toyama Pharmaceutical Co., Ltd., specialized in sales and marketing of prescription drugs in Japan.

Markets: The company’s major pharmaceutical product line Clarith is marketed throughout Abbott Laboratories of the U.S. to approximately 90 countries. The company also operates in Asia markets, Europe and United Kingdom markets.

Significant Events

Bayer Schering Pharma AG has entered into a license and option agreement with Taisho Pharmaceutical Co., Ltd., Nihon Nohyaku Co. Ltd., and the National Institute of Radiological Sciences (NIRS), Japan, to develop imaging compounds for the detection of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and other disorders also associated with neuroinflammation such as multiple sclerosis.

Chugai Pharmaceutical Co., Ltd. and Taisho Pharmaceutical Co., Ltd. would co-develop and market antiresorptive bisphosphonate R484, (generic name: ibandronic acid) for treatment of osteoporosis in post-menopausal women. R484 is in phase II clinical trials in Japan. It is marketed under the brand name Bonviva in the U.S.

Pfizer, Inc. has signed a collaboration deal with Taisho Pharmaceutical Co. Ltd. to research, develop and commercialize TS-032, a new schizophrenia drug candidate discovered by Taisho and in pre-clinical development. Taisho would grant development and commercialization rights outside Japan for TS-032 to Pfizer.

Roche's Japanese subsidiary, Chugai has entered into an agreement with Taisho Pharmaceutical Co., Ltd. to co-develop and co-market ED-71 (eldecalcitol), an activated vitamin D derivative that Chugai is developing in Japan for the treatment of osteoporosis.

History

Taisho Pharmaceutical Company, Ltd. was founded in 1912.

The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

Contents

RESEARCH METHODOLOGY

DISCLAIMER

1. TAISHO PHARMACEUTICAL CO. LTD. COMPANY PROFILE

1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History

2. TAISHO PHARMACEUTICAL CO. LTD. BUSINESS OVERVIEW

2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units

3. TAISHO PHARMACEUTICAL CO. LTD. SWOT ANALYSIS

3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats

4. TAISHO PHARMACEUTICAL CO. LTD. FINANCIAL ANALYSIS

4.1. Financial Statements
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.1. Profitability
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot

5. TAISHO PHARMACEUTICAL CO. LTD. COMPETITORS AND INDUSTRY ANALYSIS

5.1. Taisho Pharmaceutical Co. Ltd. Direct Competitors
5.2. Comparison of Taisho Pharmaceutical Co. Ltd. and Direct Competitors Financial Ratios
5.3. Comparison of Taisho Pharmaceutical Co. Ltd. and Direct Competitors Stock Charts
5.4. Taisho Pharmaceutical Co. Ltd. Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. Taisho Pharmaceutical Co. Ltd. Industry Position Analysis

6. TAISHO PHARMACEUTICAL CO. LTD. NEWS & EVENTS

6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events

7. TAISHO PHARMACEUTICAL CO. LTD. EXPERTS REVIEW¹

7.1. Experts Consensus
7.2. Experts Revisions

8. TAISHO PHARMACEUTICAL CO. LTD. ENHANCED SWOT ANALYSIS²

9. JAPAN PESTEL ANALYSIS²

9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors

10. TAISHO PHARMACEUTICAL CO. LTD. IFE, EFE, IE MATRICES²

10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix

11. TAISHO PHARMACEUTICAL CO. LTD. PORTER FIVE FORCES ANALYSIS²

12. TAISHO PHARMACEUTICAL CO. LTD. VRIO ANALYSIS²

APPENDIX: RATIO DEFINITIONS

LIST OF FIGURES

Taisho Pharmaceutical Co. Ltd. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Taisho Pharmaceutical Co. Ltd. 1-year Stock Charts
Taisho Pharmaceutical Co. Ltd. 5-year Stock Charts
Taisho Pharmaceutical Co. Ltd. vs. Main Indexes 1-year Stock Chart
Taisho Pharmaceutical Co. Ltd. vs. Direct Competitors 1-year Stock Charts
Taisho Pharmaceutical Co. Ltd. Article Density Chart

1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

List Of Tables

LIST OF TABLES

Taisho Pharmaceutical Co. Ltd. Key Facts
Profitability
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Taisho Pharmaceutical Co. Ltd. Key Executives
Taisho Pharmaceutical Co. Ltd. Major Shareholders
Taisho Pharmaceutical Co. Ltd. History
Taisho Pharmaceutical Co. Ltd. Products
Revenues by Segment
Revenues by Region
Taisho Pharmaceutical Co. Ltd. Offices and Representations
Taisho Pharmaceutical Co. Ltd. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Taisho Pharmaceutical Co. Ltd. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Taisho Pharmaceutical Co. Ltd. Capital Market Snapshot
Taisho Pharmaceutical Co. Ltd. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Taisho Pharmaceutical Co. Ltd. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Taisho Pharmaceutical Co. Ltd. Consensus Recommendations¹
Analyst Recommendation Summary¹
Price Target Summary¹
Experts Recommendation Trends¹
Revenue Estimates Analysis¹
Earnings Estimates Analysis¹
Historical Surprises¹
Revenue Estimates Trend¹
Earnings Estimates Trend¹
Revenue Revisions¹

ANALYSIS FEATURES

SWOT Analysis

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

• How to use the strengths to take advantage of the opportunities?
• How to use the strengths to reduce likelihood and impact of the threats?
• How to overcome the weaknesses that obstruct taking advantage of the opportunities?
• How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

• Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
• Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
• Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
• Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
• Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
• Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.

Porter Five Forces Analysis

The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

1. What composes a threat of substitute products and services?
2. Is there a threat of new competitors entering the market?
3. What is the intensity of competitive rivalry?
4. How big is the bargaining power of buyers?
5. How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:

• Tangible resources
  • Financial
  • Physical
  • Technological
  • Organizational
• Intangible resources
  • Human
  • Innovation and Creativity
  • Reputation
• Organizational capabilities

The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:

• Valuable?
• Rare?
• Costly to imitate?
• Organized properly?